» Articles » PMID: 16173048

Roles of Osteonectin in the Migration of Breast Cancer Cells into Bone

Overview
Journal J Cell Biochem
Date 2005 Sep 21
PMID 16173048
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The focus of this study was to gain insight into the role(s) of osteonectin in the preferential metastasis of breast cancer cells to bone. Osteonectin was isolated from conditioned media of several cell lines including breast cancer (MDA-MB-435, MDA-MB-468), osteoblasts (hFOB1.19), non-neoplastic breast epithelial (hTERT-HME1), and vascular endothelial cells isolated from a bone biopsy (HBME-1). Chemical/physical properties of osteonectin from these five sources was analyzed to determine if unique configurations of osteonectin exist and therefore identify a chemotactic isoform. Osteonectin from all sources had a molecular weight of approximately 46 kDa, N-linked glycosylation, and undetectable phosphorylated serines, sialic acids and O-linked oligosaccharides. The cDNA for osteonectin from the breast cancer, osteoblast, and breast epithelial cell lines was identical, while the vascular endothelial cell cDNA contained point mutations that resulted in eight amino acid substitutions. Bone-derived osteonectin was then analyzed to assess its influence on breast cancer cell motility and migration. Although osteonectin increased undirected MDA-MB-231 cell motility, it did not chemoattract the same breast cancer cell line. However, the breast cancer cells did migrate toward the known chemoattractant vitronectin and to bone extracts derived from wild-type and osteonectin-null mice. Migration to vitronectin was enhanced when osteonectin was also present. We concluded that osteonectin was not a chemotactic factor. However, through its anti-adhesive properties, osteonectin induced undirected breast cancer cell motility, and may have enhanced chemoattraction to vitronectin.

Citing Articles

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.

Natkin R, Pennanen P, Syvala H, Blauer M, Kesseli J, Tammela T PLoS One. 2023; 18(2):e0281645.

PMID: 36809527 PMC: 9942993. DOI: 10.1371/journal.pone.0281645.


SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.

Alcaraz L, Mallavialle A, Mollevi C, Boissiere-Michot F, Mansouri H, Simony-Lafontaine J Int J Cancer. 2022; 152(6):1243-1258.

PMID: 36346290 PMC: 10099777. DOI: 10.1002/ijc.34345.


A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.

Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C Theranostics. 2021; 11(13):6173-6192.

PMID: 33995652 PMC: 8120228. DOI: 10.7150/thno.58254.


Matricellular proteins as regulators of cancer metastasis to bone.

Trotter T, Yang Y Matrix Biol. 2016; 52-54:301-314.

PMID: 26807761 PMC: 4875810. DOI: 10.1016/j.matbio.2016.01.006.


SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.

Mateo F, Meca-Cortes O, Celia-Terrassa T, Fernandez Y, Abasolo I, Sanchez-Cid L Mol Cancer. 2014; 13:237.

PMID: 25331979 PMC: 4210604. DOI: 10.1186/1476-4598-13-237.